Description
Retatrutide (GLP-3) is a novel multi-agonist peptide engineered to simultaneously target GLP-1, GLP-2, and GIP receptors. This triple-receptor mechanism distinguishes it from single or dual-agonist compounds and has made it a high-interest compound in metabolic and obesity research.
In laboratory models, Retatrutide has been studied for its potential to regulate insulin secretion, suppress appetite, improve glucose homeostasis, and influence energy expenditure. By engaging multiple gut hormone receptor pathways at once, it represents a new frontier in experimental research on metabolic disease, weight regulation, and endocrine function.
Key Research Features:
– Triple Receptor Agonism: Acts on GLP-1, GLP-2, and GIP receptors simultaneously in research models
– Glucose Regulation: Studied for effects on insulin sensitivity and blood sugar homeostasis
– Weight Management Research: Investigated for appetite suppression and energy balance in laboratory studies
– Metabolic Efficiency: Explored for its influence on multiple metabolic signaling pathways
– Research-Grade Quality: Intended strictly for laboratory and scientific research purposes only




Reviews
There are no reviews yet.